CA
NZ
UK
AU
IND
US
Climb Bio, Inc. (NASDAQ: CLYM) has begun dosing its first patient in a Phase 2 clinical trial that focuses on immunoglobulin A nephropathy. This marks a key moment for the company's efforts in advancing treatmentOptionsfor patients affected by this condition. The collaboration with Beijing …
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has officially suspended all orders and shipments of its biocosmeceutical products, including the ExoCR and BioX lines, effective August 7, 2026. This suspension is part of a strategic review aimed at evaluating the regulatory compliance and documentation associated with …
Cerenome, Inc. posted a net loss of $9 million, or $1.31 per share, for the second quarter ending June 30, 2026. This figure contrasts sharply with a net income of $5.2 million during the same quarter in 2025. The shift in financial performance is …
BeyondSpring Inc. (NASDAQ: BYSI) reported a net loss of $1.8 million for the second quarter ending June 30, 2026, slightly improved from a $1.9 million loss in the same quarter a year prior. The company’s financial updates coincide with a strategic leadership transition aimed …
BioAffinity Technologies, Inc. has raised approximately $3.6 million through a private placement that includes the issuance of pre-funded warrants and common stock. This move significantly enhances the company'sLiquidityposition, providing resources essential for future operational initiatives. The successful closing of this placement on August 14, …
Aptevo Therapeutics Inc. (NASDAQ: APVO) reported compelling clinical data for its lead candidate mipletamig, demonstrating an 87% clinical benefit rate among frontline acute myeloid leukemia (AML) patients. The performance highlights mipletamig's potential effectiveness when combined with existing treatments, reinforcing Aptevo's strategic focus on improving …
Assembly Biosciences, Inc. (NASDAQ: ASMB) has successfully secured $115 million in gross financing, aCapitalinfusion that directly bolsters itsBalance Sheetand expands the runway for itsDrug Developmentactivities. By adding this financing to an existing cash pool of $320.4 million, the company has effectively increased its liquidity …
Allarity Therapeutics, Inc. (NASDAQ: ALLR) concluded the second quarter of 2026 with a solid cash position of $26.9 million, comprising both cash and restricted cash. This figure represents a substantial increase from the previous year's cash total of $14.7 million, enhancing the company's ability …
AnaptysBio (NASDAQ: ANAB) is a clinical‑stage biotechnology firm with aMarket Capitalisationof $1.73 billion, 29,030,784 shares outstanding and $248.47 million in cash. The company reported trailing‑twelve‑month revenue of $232.39 million, a 107.7% increase year‑over‑year, but posted a net margin of -11.5% and aReturn on Equityof …
Achieve Life Sciences, Inc. (NASDAQ: ACHV) has established an at-the-market (ATM) offering program allowing the sale of common stock worth up to $150 million. This initiative was formalized in an agreement with Jefferies LLC and empowers the company to issue shares as needed through …
Please wait processing your request...